How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

13,940 results for

Diarrhea in Cancer

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. A Case of Carcinoid Syndrome Due to Malignant Metastatic Carcinoid Tumor with Carcinoid Heart Disease Involving Four Cardiac Valves Full Text available with Trip Pro

A Case of Carcinoid Syndrome Due to Malignant Metastatic Carcinoid Tumor with Carcinoid Heart Disease Involving Four Cardiac Valves BACKGROUND Carcinoid tumor, benign, low-grade malignant, and high-grade malignant, can be associated with the release of vasoactive substances that cause symptoms including cutaneous flushing, diarrhea, and bronchospasm. In 50-60% of patients with carcinoid syndrome, the vasoactive substances cause fibrosis of the pulmonary and tricuspid heart valves which lead (...) appendiceal carcinoid tumor with bilateral ovarian metastases. Post-operatively, a computed tomography (CT) scan showed cardiomegaly. Transthoracic echocardiography showed morphologic changes that affected all four heart valves, consistent with carcinoid heart disease but without a patent foramen ovale (PFO). The patient was evaluated for valve replacement surgery, but surgery was not performed due to the degree of heart failure. CONCLUSIONS This report describes a rare case of carcinoid heart disease

2018 The American journal of case reports

2. Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Cholangiocellular Carcinoma Sarcoma Desmoid Tumour Adenoid Cystic Carcinoma Non-hodgkin Lymphoma Glomus Tumor, Malignant Drug: CB-103 Phase 1 Phase 2 Detailed Description: This Phase I/IIA, open label, multicenter, dose escalation study of CB-103 in patients with Advanced or Metastatic Solid Tumours and Haematological Malignancies. After providing signed informed consent, patients will be screened for entry into the study. The study will be conducted in 2 stages: dose escalation in Part A of the study followed (...) , fibrosarcoma), desmoid tumours, adenoid cystic carcinoma, and malignant glomus tumour. Patients with histologically or cytologically confirmed, advanced haematological malignancies) whose disease has relapsed or progressed upon standard therapy and for whom at that point no standard therapy exists: Non-Hodgkin lymphomas (NHL): Follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, marginal zone B cell lymphoma (MZCL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma

2018 Clinical Trials

3. Gastrointestinal malignant neoplasms disguised as pneumatosis cystoids intestinalis: A case report and literature review. Full Text available with Trip Pro

Gastrointestinal malignant neoplasms disguised as pneumatosis cystoids intestinalis: A case report and literature review. Pneumatosis cystoids intestinalis (PCI) is a rare disease in which gas develops in the mucosa or submucosa of the digestive tract. The etiology and pathogenesis of this disease, at present, remain unclear, and gastrointestinal malignant neoplasms may be a potentially important cause. Herein, we report a case of mantle cell lymphoma presenting as PCI as well as present (...) a literature review of cases of suspect PCI that was definitively diagnosed as gastrointestinal neoplasms. In doing so, we highlighted cases of neoplastic pathogenesis that present as PCI.A 55-year-old man was referred to our gastrointestinal department with complaints of intermittent abdominal pain, distention, diarrhea, and occasional melena that persisted for 2 months. He has a history of nasopharyngeal carcinoma.Intensive, translucent, grape-like cystoids of the whole colon and small intestine were

2017 Medicine

4. Niraparib (Zejula) - Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

first detected in advanced stages when prognosis is poor. Assessment report EMA/648982/2017 Page 10/122 The 5-year overall survival rate of ovarian cancer patients is 46% across all stages and only 29% in patients diagnosed with distant metastatic disease. Most patients will die within 3 to 4 years of diagnosis [Coleman et al 2013]. 2.1.5. Management The majority of patients with ovarian cancer receive surgery to remove or debulk the tumour. The primary treatment of advanced-stage ovarian cancer (...) Resonance Non-gBRCAmut without a germline BRCA mutation NOR Normal Operating Range OAT organic anion transporter OATP organic anion transport polypeptide OCT organic cation transporter OCT Pool ovarian cancer treatment pool OS overall survival OVAT One variable at a time PAR Proven Acceptable Range PARP-1, -2 poly (ADP-ribose) polymerase 1, 2 PBMC peripheral blood mononuclear cells PD progressive disease PDX patient-derived xenograft PFS progression-free survival PFS2 progression-free survival 2 PGI

2017 European Medicines Agency - EPARs

5. Phase I Study of AZD5363 + Olaparib + Durvalumab (MEDI4736) in Patients With Advanced or Metastatic Solid Tumor Malignancies

only if polymerase chain reaction is negative for HCV RNA Renal failure requiring haemodialysis or peritoneal dialysis; Clinically unstable, active infection requiring systemic antibiotics; Concurrent cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off all therapy for that disease for a minimum of 3 years; Patients with significantly diseased or obstructed gastrointestinal tract, malabsorption, uncontrolled vomiting or diarrhea (...) with advanced or metastatic solid tumor malignancies. The purpose of this trial is to determine if combination treatment of drugs, Olaparib, AZD5363 and Durvalumab has beneficial effects in advanced or metastatic cancers and to determine the effects it has on patients and their cancer. Primary Objectives • To evaluate the safety and tolerability of combination treatment AZD5363 + Olaparib + Durvalumab and determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicities (DLTs), and Recommended Phase 2

2018 Clinical Trials

6. Neratinib (Nerlynx) - Breast cancer, breast neoplasms

disease-free survival DFS-DCIS disease-free survival including ductal carcinoma in situ ECG electrocardiogram ECOG Eastern Cooperative Oncology Group EGFR epidermal growth factor receptor EQ-5D EuroQol 5-Dimension Questionnaire ER estrogen receptor ERBB erythroblastic leukemia viral oncogene homolog; also termed HER ExteNET Extended Adjuvant Treatment of Breast Cancer with Neratinib FACT-B Functional Assessment of Cancer Therapy-Breast FMO flavin-containing monooxygenase GI gastrointestinal HER human (...) Neratinib (Nerlynx) - Breast cancer, breast neoplasms 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 13 July 2018 EMA/CHMP/525204/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Nerlynx International

2018 European Medicines Agency - EPARs

7. Cell-Free Circulating Tumour DNA Blood Testing to Detect EGFR T790M Mutation in People With Advanced Non–Small Cell Lung Cancer

: about 60% of NSCLCs are adenocarcinoma. Former or current smoking is often a causal factor in all forms of lung cancer. However, nonsmokers with lung cancer frequently have adenocarcinoma. This type of cancer is usually found on the outer parts of the lung. People with adenocarcinoma tend to have better survival than people with other types of lung cancer • Squamous cell (epidermoid) carcinoma: 25% to 30% of all NSCLCs are squamous cell carcinomas. Squamous cells are flat cells that line the inside (...) • Other subtypes: Less common NSCLC subtypes include adenosquamous carcinoma and sarcomatoid carcinoma The progression of cancer is divided into four stages; a higher number signifies more extensive disease. In stage 1, the cancer is confined to the original site within the lung and there is no sign of spread to lymph nodes (N0) or elsewhere (M0). In stage 2, the cancer has spread to lymph nodes within the lung (N1). In stage 3, the cancer has spread to lymph nodes in the middle of the chest

2020 Health Quality Ontario

8. Melatonin Immunoreactivity in Malignant Small Intestinal Neuroendocrine Tumours. Full Text available with Trip Pro

Melatonin Immunoreactivity in Malignant Small Intestinal Neuroendocrine Tumours. Small intestinal neuroendocrine tumours (SI-NETs) are derived from enterochromaffin cells. After demonstrating melatonin in enterochromaffin cells, we hypothesized that SI-NETs may express and secrete melatonin, which may have an impact on clinical factors and treatment response.Tumour tissue from 26 patients with SI-NETs, representing paired sections of primary tumour and metastasis, were immunohistochemically (...) stained for melatonin and its receptors, MT1 and MT2. Plasma melatonin and immunoreactivity (IR) for melatonin, MT1 and MT2 in tumour cells were compared to other tumour markers and clinical parameters. Melatonin was measured at two time points in fasting morning plasma from 43 patients with SI-NETs.Melatonin IR was found in all SI-NETS. Melatonin IR intensity in primary tumours correlated inversely to proliferation index (p = 0.022) and patients reported less diarrhoea when melatonin IR was high (p

2016 PLoS ONE

9. Comparison of long-term benefits of organ-preserving pancreatectomy techniques for benign or low-grade malignant tumors at the pancreatic head. Full Text available with Trip Pro

Comparison of long-term benefits of organ-preserving pancreatectomy techniques for benign or low-grade malignant tumors at the pancreatic head. The aim of this article was to investigate and emphasize the clinical benefits of organ-preserving surgeries by comparing the pancreatic head resection with segmental duodenectomy (PHRSD), pylorus-preserving pancreatoduodenectomy (PPPD), and classic pancreatoduodenectomy (PD).A retrospective analysis of PHRSD (20 patients), PPPD (42 patients), and PD (...) (92 patients) with benign lesions, low-grade malignancies, or early-stage carcinomas at the pancreatic head was performed since 2008. The intraoperative and postoperative courses and a long-term statuses were compared.The overall average age of the patients in 3 groups was 48.82 years old (range 12-76). The mean operative time and the blood loss were significantly less in the PHRSD and PPPD groups than that in the PD group (P < .05), but there were no differences between the PHRSD and PPPD groups

2017 Medicine

10. Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies

that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) Presence of a psychiatric illness or social situation that would limit compliance with study requirements Women who are pregnant or breastfeeding The subject must not have had diagnosis, detection, or treatment of another type of cancer ≤2 years prior to randomization (except basal or squamous cell carcinoma of the skin (...) criteria. Condition or disease Intervention/treatment Phase Solid Tumor, Adult Homologous Recombination Deficiency Drug: Niraparib Drug: Carboplatin Phase 1 Detailed Description: This is a multi-institutional Phase I dose-escalation and dose-expansion trial for patients with advanced, solid tumor malignancies who have pre-identified deleterious germline or somatic mutations in the homologous recombination deoxyribonucleic acid (DNA) repair pathway (HR deficient). The trial is designed to assess

2017 Clinical Trials

11. Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms

the Committee, issued a positive opinion for granting a marketing authorisation to Tookad on 14 September 2017. 2. Scientific discussion 2.1. Problem statement 2.1.1. Disease or condition Tookad is indicated as monotherapy for adult patients with previously untreated, unilateral, low-risk, adenocarcinoma of the prostate with a life expectancy = 10 years and: - Clinical stage T1c or T2a, - Gleason Score = 6, based on high-resolution biopsy strategies, - PSA = 10 ng/mL, - 3 positive cancer cores (...) Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 14 September 2017 EMA/644309/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report TOOKAD International non-proprietary name: padeliporfin Procedure No. EMEA/H/C/004182/0000 Note Assessment report

2017 European Medicines Agency - EPARs

12. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Full Text available with Trip Pro

Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Adenoid cystic carcinoma (ACC) is a subtype of malignant salivary gland tumors (MSGT), in which 90% of cases express cKIT. Dasatinib is a potent and selective inhibitor of five oncogenic protein tyrosine kinases (PTKs)/kinase families including cKIT. We conducted a phase II study to determine the antitumor activity of dasatinib in ACC and non-ACC (...) or higher) were: fatigue (28%), nausea (19%), headache (15%), lymphopenia (7%), dyspnea (11%), alanine aminotransferase increased (7%), anorexia (7%), vomiting (7%), alkaline phosphatase increased (6%), diarrhea (6%), neutropenia (6%), and noncardiac chest pain (6%). No grade 4 AE occurred, 15 patients experienced a grade 3 AE, primarily dyspnea (5) and fatigue (4), and cardiac toxicity (1 prolonged QTc). Among ACC patients, best response to dasatinib: 1 patient (2.5%) had partial response, 20 patients

2016 Annals of Oncology

13. Ribociclib, Breast Neoplasms, Benefit Assessment, NCT02422615, NCT02278120

breast cancer were included. Randomization was in a 1:1 ratio and was stratified according to the presence of liver or lung metastases (yes/no), prior chemotherapy for advanced disease (yes/no) and endocrine combination partner (tamoxifen + goserelin or NSAI + goserelin). All patients in the study were pre- or perimenopausal. Their tumours had to be not amenable to resection or radiotherapy with curative intent. In addition, the patients had to have an Eastern Cooperative Oncology Group Performance (...) Ribociclib, Breast Neoplasms, Benefit Assessment, NCT02422615, NCT02278120 Extract 1 Translation of Sections 2.1 to 2.8 of the dossier assessment Ribociclib (Mammakarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 April 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-06 Ribociclib (breast cancer

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

14. Conundrum of a Large Bowel Neoplasm: Collision Tumor Full Text available with Trip Pro

Conundrum of a Large Bowel Neoplasm: Collision Tumor A 79-year-old Hispanic man was admitted to the intensive care unit with symptomatic iron-deficiency anemia and watery diarrhea. Radiological images revealed diffuse colonic wall thickening, a soft-tissue fullness in the ascending colon, and multiple mesenteric lymphadenopathies. Colonoscopy showed multiple aphthous ulcers throughout the colon and a large deep ulcer with irregular raised borders in the rectosigmoid area. Histological exam (...) of the ulcers showed severe ulcerative colitis, while biopsy of the deep ulcer revealed a well-differentiated adenocarcinoma. Colectomy specimen was consistent with colliding diffuse large B-cell lymphoma and adenocarcinoma.

2018 ACG case reports journal

15. Chiefs’ inquiry corner: monoclonal antibodies and clostridium difficile infection, outcomes after in-hospital cardiac arrest v out-of-hospital, dermatomyositis and malignancy, malignancy work up in unprovoked VTE.

identified. Of the types of myositis, patients with dermatomyositis had the highest incidence of malignancy, with 42% of patients diagnosed with malignant disease, leading to a standardized incidence ratio of 6.2 (95% CI 3.9 to 10.0]. Polymyositis was also associated with malignant disease, though to a lesser degree with a standardized incidence ratio of only 2.0 (CI 1.4 to 2.7). The most common types of malignancy diagnosed are adenocarcinomas, including lung, gastric, ovarian, and pancreatic, though (...) Chiefs’ inquiry corner: monoclonal antibodies and clostridium difficile infection, outcomes after in-hospital cardiac arrest v out-of-hospital, dermatomyositis and malignancy, malignancy work up in unprovoked VTE. Chiefs’ Inquiry Corner – Clinical Correlations Search Chiefs’ Inquiry Corner June 10, 2019 3 min read Clostridium difficile (C diff) is the most common pathogen implicated in infectious diarrhea among hospitalized patients. Several antimicrobials, chief among them an oral formulation

2019 Clinical Correlations

16. Rucaparib camsylate - Ovarian Neoplasms

/238139/2018 Page 10/167 2. Scientific discussion 2.1. Problem statement 2.1.1. Disease or condition The applied indication for Rubraca, was as monotherapy in the treatment of advanced ovarian cancer in adult patients with deleterious BRCA mutated tumours, inclusive of both germline BRCA and somatic BRCA mutations, and who have been treated with two or more prior lines of chemotherapy. The approved indication is as monotherapy treatment of adult patients with platinum sensitive, relapsed (...) replacement therapy confer increased risks. These associations differ by histologic subtypes (histotype), especially for mucinous OC, likely reflecting differences in aetiology. The prevalence of ovarian cancer is currently estimated at 4.7 in 10,000. Ovarian cancer is the leading cause of death attributed to gynaecological cancer in the developed world (World Cancer Report 2014, WHO, Chapter 5.12). 2.1.3. Biologic features Nearly all benign and malignant ovarian tumours originate from one of three cell

2018 European Medicines Agency - EPARs

17. Gastroenteropancreatic Neuroendocrine Neoplasms

(NENs) arise from the diffuse neuroendocrine cell system and may occur at many different disease sites. Most frequently, these neoplasms occur in the digestive system, followed by the lung. The term NEN encompasses well- differentiated neuroendocrine tumours (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). NECs represent only 10%–20% of all NENs. The main focus of these guidelines is on sporadic small intestinal (SI)-NENs and pancreatic NENs (Pan-NENs) since these are the most (...) Neuroendocrine Tumour Society (ENETS) was recently widely adopted by the eighth edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) staging system [11] for various types of GEP-NETs. For all NECs, the staging system of adenocarcinomas must be applied [11]. Furthermore, the primary tumour site has an impact on the prognosis in advanced disease. 6 Patients with Pan-NETs or colorectal NETs have a less favourable prognosis than patients with small intestinal

2020 European Society for Medical Oncology

18. Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy

adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy' . Ramucirumab monotherapy is indicated for 'the treatment of adult patients with advanced gastric cancer or gastro–oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate' . 2.2 Ramucirumab is given as an intravenous infusion over about 60 minutes. Ramucirumab is a human receptor (...) or gastro–oesophageal junction adenocarcinoma who had disease progression on or within 4 months after the last dose of treatment with first-line, platinum-containing or Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 9 of 45fluoropyrimidine-containing chemotherapy, or on or within 6

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

19. ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma Full Text available with Trip Pro

with malignant lymphoma | Annals of Oncology | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation March 2018 Article Contents Article Navigation ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma C Buske Comprehensive Cancer Center Ulm and Department (...) , ∼18.9% of the population in the European Union were ≥65 years old; specifically, 4.4% were 70–74, 3.8% were 75–79 and 5.3% were ≥80 years old [ ]. Moreover, by 2060, it is estimated that the proportion of people ≥65 years old will rise to 28% and the proportion who are ≥80 years old will rise to 12% [ ]. Consequently, the number of elderly patients with haematological malignancies will rise continuously and dramatically since they are typical diseases of the elderly, with a median age at initial

2018 European Society for Medical Oncology

20. Tumour lysis syndrome

with lymphomas and leukaemias, in particular Burkitt's lymphoma and acute lymphoblastic leukaemia. It is also associated with other haematological malignancies and solid tumours. History and exam history of haematological malignancy pre-existing renal compromise syncope/chest pain/dyspnoea seizures nausea and vomiting anorexia diarrhoea muscle weakness muscle cramps lethargy paraesthesia lymphadenopathy splenomegaly hypertension/hypotension oliguria/anuria/haematuria solid tumour malignancy laryngeal spasm (...) Tumour lysis syndrome Tumour lysis syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Tumour lysis syndrome Last reviewed: February 2019 Last updated: March 2018 Summary Defined as a combination of metabolic and electrolyte abnormalities occurring spontaneously or following initiation of cytotoxic treatment in patients with cancer. It is characterised by excessive cell lysis. Most commonly associated

2018 BMJ Best Practice

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>